The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT 2024 | Optimizing haplo-SCT for the treatment of AML
Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, discusses advancements in haploidentical stem cell transplantation (haplo-SCT) for the treatment of acute myeloid leukemia (AML). He discusses the use of post-transplant cyclophosphamide (PTCy) to mitigate graft-versus-host disease (GvHD), with the potential addition of anti-thymocyte globulin (ATG). He also points out the benefits of using non-myeloablative conditioning, especially for older patients. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
